Macrogenics (MGNX) Gains from Investment Securities (2013)
Macrogenics (MGNX) posted quarterly Gains from Investment Securities of $554000.0 for Q3 2013, up 1236.42% quarter-over-quarter from $41454.0 in Q2 2013.
Powered by 
Analysis
Macrogenics (MGNX) Gains from Investment Securities (2013) Analysis & Trends
Macrogenics (MGNX) has reported Gains from Investment Securities for 1 consecutive years, with $554000.0 the latest figure, recorded in Q3 2013.
- In Q3 2013, Gains from Investment Securities changed N/A year-over-year to $554000.0; the TTM figure through Dec 2013 stood at $626000.0 (changed N/A YoY), while the FY2013 annual figure was $626000.0, up 514.57% from the prior year.
- Gains from Investment Securities grew to $554000.0 in Q3 2013 per MGNX's latest filing, from $41454.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $554000.0 in Q3 2013 and bottomed at $30546.0 in Q1 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2013 | 554,000.00 |
| Jun 30, 2013 | 41,454.00 |
| Mar 31, 2013 | 30,546.00 |